ESC 2017: The GLAGOV Trial - Stephen Nicholls

 

This interview with Stephen Nicholls from South Australian Health and Medical Research Institute, Adelaide, AU on the Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis (GLAGOV) at ESC 2017.